« Return to News | CROs/Service Providers

QED Clinical Services to launch OrphanReach drug development division

Thursday, August 30, 2012 11:13 AM

QED Clinical Services, a global niche CRO operating, is launching OrphanReach, a division to develop drugs in rare disease areas.

OrphanReach will capitalize on QED’s global infrastructure, while employing a flexible, adaptive approach, providing a good fit with orphan drug development needs.

"We can clearly see a strong industry trend for orphan drug development activities,” said Thomas Ogorka, CEO of QED. “Any company developing drugs for orphan indications needs a service provider who can not only offer tailor-made solutions in a very effective and attentive way, but also has access to these rare patient populations no matter where in the world.”

Ogorka continued, “QED's new OrphanReach division offers our sponsors exactly that: a lean management structure with excellent client attention and at the same time the global reach element which one would have thought only the largest CROs can provide. QED is a good example that an innovative operational model can work perfectly well in combination with niche areas like the development of orphan and rare disease drugs thus providing sponsors with a powerful CRO alternative."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.